"The National Aeronautics and Space Administration (NASA) has identified a potential pharmaceutical industry partner named Epiomed Therapeutics, Inc., having its principal place of business in Irvine, California, which is interested in assuming responsibilities for the further development and commercialization of a pharmaceutical dosage form for intranasal administration of scopolamine (INSCOP). NASA has been actively engaged in the clinical development of this agent and is now seeking a Space Act Agreement (SAA) Partner whose role will include production of the formulation under FDA stipulated GMP GUIDELINES for clinical trials."
Keith's note: No mention of CASIS - anywhere. Isn't this the sort of thing CASIS is supposed to be doing?